巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Avadel Pharmaceuticals plc

    AVDL
    3.630
    0.050
    1.40%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Avadel Pharmaceuticals plc - 延遲價格・最後更新於 06/07 6:53
    最高位
    3.920
    最低位
    3.385
    開市價
    --
    前收市價
    3.580
    成交量(千)
    36.14
    成交額(百萬)
    1.21
    買入
    3.610
    賣出
    3.660
    每手股數
    --
    市值(百萬)
    214.31
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    11.590 - 1.050
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Avadel Pharmaceuticals plc
    證券代碼
    AVDL.US
    所屬板塊
    Drug Manufacturers - Specialty & Generic
    公司業務
    Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.
    發行量
    59032237
    公司總部
    10 Earlsfort Terrace, Dublin 2
    公司網址
    https://www.avadel.com
    公司電話
    +353 19015201
    暫無內容

    關於

    Avadel Pharmaceuticals plc(AVDL.US)所屬的行業板塊為Drug Manufacturers - Specialty & Generic。
    Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.
    詳細公司背景可參考: https://www.avadel.com